A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication
Completed
Conditions studied: HIV Infection
In brief
This is a prospective, observational study to describe pregnancy outcomes among HIV-1 uninfected pregnant women who are taking emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication nested in the Antiretroviral Pregnancy Registry (APR). Information on subjects is provided to the APR prospectively (prior to the outcome of the pregnancy being known) through their healthcare provider, with follow-up obtained from the healthcare provider following determination of the pregnancy outcome.
Key facts
- Study ID
- NCT01865786
- Run by
- Gilead Sciences
- People needed
- 99
- Starts
- 2013-01-01
- Expected to finish
- 2018-03-13
- Last updated by the study team
- 2018-03-30
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Antiretroviral Pregnancy Registry — Wilmington, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.